Topoisomerase II inhibitors CX-5461 and Doxorubicin differ in their cardiotoxicity profiles
Sayan Paul, Jose A. Gutierrez, Alyssa R. Bogar, E. Renee Matthews, Michelle C. Ward
This study compares the cardiotoxicity of CX-5461 and Doxorubicin in iPSC-derived cardiomyocytes, finding CX is less cytotoxic and induces fewer gene expression changes.
G3 Genes Genomes Genetics · Jan 16, 2026Peer-reviewedGenomics